Prosecution Insights
Last updated: April 19, 2026

Xilio Therapeutics

5 pending office actions • 1 client

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Client Portfolio (1 client)

Client (Assignee)Pending OAs
Xilio Development, Inc. 5

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
18352762 ENGINEERED CLEAVABLE CARRIERS AND METHODS OF USE THEREOF Xilio Development, Inc. FORD, VANESSA L 1674 Non-Final OA Jul 14, 2023
18115527 TARGETED CYTOKINES AND METHODS OF USE THEREOF Xilio Development, Inc. BUNNER, BRIDGET E 1647 Non-Final OA Feb 28, 2023
17995163 MASKED IL-2 CYTOKINES AND THEIR CLEAVAGE PRODUCTS Xilio Development, Inc. JUEDES, AMY E 1644 Non-Final OA Sep 30, 2022
17995162 MASKED IL-12 CYTOKINES AND THEIR CLEAVAGE PRODUCTS Xilio Development, Inc. GURLEY, JAMI MICHELLE 1647 Final Rejection Sep 30, 2022
17932057 CLEAVABLE LINKERS Xilio Development, Inc. YOUTCHOM PENDIE, EMMANUEL LED 1647 Non-Final OA Sep 14, 2022

Managing Xilio Therapeutics's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month